Frequency of symptoms in different stages of pancreatic cancer
Objectives Symptoms of pancreatic adenocarcinoma are usually not specific and often they are missed by doctors and not noticed seriously by patients for early diagnosis of this disease. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Stefan Krstevski Tags: 8. Pancreatic Cancer I Source Type: research
Adjuvant chemotherapy after surgery for invasive Intraductal papillary mucinous neoplasms of the pancreas: the potential survival benefit depends on the specific subtype
Objectives Little is known about the role of adjuvant treatment after surgery for malignant Intraductal Papillary Mucinous Neoplasms (IPMNs). The aim of this study is to assess the potential role of adjuvant chemotherapy in terms of improvement of survival. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Giovanni Marchegiani, Chiara Dal Borgo, Stefano Andrianello, Erica Secchettin, Davide Melisi, Giuseppe Malleo, Claudio Bassi, Roberto Salvia Tags: 8. Pancreatic Cancer I Source Type: research
18 FDG PET/CT derived prognostic parameters in patients with pancreatic cancer
Objectives Pancreatic cancer is a devastating disease with poor long term outcomes. 18 FDG PET/CT provides functional and anatomical data in metabolically active tumours that can influence the management decisions and inform the overall prognosis. Patients with a high maximum standardized uptake value (SUVmax) are known to have a poor long term prognosis however, SUVmax provides a single voxel value within a region of interest and therefore may not account for the overall burden of the disease (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Eyas Mohamed, Bal Sanghera, Wailup Wong, Paula Ghaneh Tags: 8. Pancreatic Cancer I Source Type: research
Nationwide treatment, outcome and predictors for survival in distal cholangiocarcinoma
This study investigated treatment, outcome and predictors for survival in a nationwide cohort of patients with distal cholangiocarcinoma. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Marin Strijker, Ali Belkouz, Lydia van der Geest, Olivier Busch, Thomas van Gulik, Joanne Verheij, Johanna Wilmink, Bas Groot Koerkamp, Heinz-Josef Kl ümpen, Dutch Pancreatic Cancer Group, Marc Besselink Tags: 8. Pancreatic Cancer I Source Type: research
Drug repurposing as a source of innovative therapies in pancreatic cancer
Objectives Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is one of the deadliest tumors with 5-year survival rates still under 10%. Few drugs have been able to make significant improvements in patient outcomes and, albeit that there is a pipeline of new agents, many fail in phase 2/3 clinical trials. Drug repurposing, an alternative development pathway, seeks to reuse existing drugs as the source of new treatment options. Repurposing benefits from existing data on safety, dosing and clinical experience. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Pan Pantziarka, Gauthier Bouche, Ilse Rooman Tags: 8. Pancreatic Cancer I Source Type: research
Pancreas resection with vein recontruction - PTFE versus autografts
Objectives Nowadays SMV-PV reconstruction during pancreatic surgery become widely performed technique in high-volume surgical centers although the choice of used vascular conduit remains an area of controversy. Prosthetic graft implantation is associated with high number of thrombotic potentially lethal complication, while autologous vein procurement was reported technically demanding and provoking unfavorable consequences. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Marek Durlik, Grzegorz Witkowski, Anna Maliszewska, Agnieszka Surowiecka-Pastewka, Ireneusz Ziobrowski, Magdalena Derejska, Marta Matejak-G órska, Tomasz Chełchowski Tags: 8. Pancreatic Cancer I Source Type: research
PAMPAC trial: Occurrence of pain and quality of pain management in pancreatic cancer patients across Europe
Objectives Pancreatic ductal adenocarcinoma (PDAC) is associated with moderate to severe cancer-related pain in most patients, as it has a high rate of neural invasion. Despite WHO management guidelines for pain management, more than 50% of cancer patients worldwide still experience pain. One-third of these patients don ’t receive an adequate pain treatment. This data indicates that there is a need for more investigations regarding pain management in PDAC patients to improve the quality of care. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Marko Damm, Anna-Katharina K ölsch, Maximilian Weniger, Stephan Schorn, John Moir, Patrick Michl, Güralp Onur Ceyhan, Jonas Rosendahl Tags: 8. Pancreatic Cancer I Source Type: research
Definition of age dependent reference values for diameter of the common bile duct and pancreatic duct on MRCP from a population based cohort study
Objectives Changes in diameters of the pancreaticobiliary ducts are markers of benign and malignant pancreaticobiliary conditions. MRCP is first line, non-invasive imaging modality. The reference ranges in asymptomatic individuals have only been studied in small cohorts. We aim define new reference values for diameters of pancreaticobiliary ducts on MRCP in the general population. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Georg Beyer, Florian Kasprowicz, Anke Hannemann, Ali Aghdassi, Henry V ölzke, Thomas Kohlmann, Jens-Peter Kühn, Markus M. Lerch, Julia Mayerle Tags: 8. Pancreatic Cancer I Source Type: research
Pancreatic cancer treatment predicted for the recurrence type and CA19-9 value
We examined a treatment strategy predicted for the types of recurrence and CA19-9 value from the resected cases of our institute. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Jun Itakura, Mitsuaki Watanabe, Naohiro Hosomura, Hidetake Amemiya, Hiromichi Kawaida, Hirotaka Okamoto, Hiroshi Kohno, Daisuke Ichikawa Tags: 8. Pancreatic Cancer I Source Type: research
Pancreatic cancer arising from the remnant pancreas after pancreatectomy: A multicenter retrospective study by the Kyushu study group of clinical cancer
Objectives After initial pancreatic resection, local recurrence of pancreatic cancer (PC) can occur in the pancreatic remnant. Additionally, new primary PC can develop in the remnant. There are limited data available regarding this so-called remnant PC. The aim of this study was to clarify the clinical features and establish the treatment strategy of remnant PC. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Daisuke Hashimoto, Kota Arima, Keisuke Miyake, Atsuko Yonemura, Shigeki Nakagawa, Akira Chikamoto, Hideo Baba Tags: 8. Pancreatic Cancer I Source Type: research
Platelet rich fibrin sealant Vivostat ® in pancreatic surgery
Objectives The Platelet-rich fibrin sealant (PRF) Vivostat is the only autologous glue that can be prepared from a patient blood directly at the operating theatre. Its use to seal pancreatostomy could be one of the ways, how to decrease the number of postoperative pancreatic fistulas (POPF) in the pancreatic surgery. Our aim was to implement the Vivostat PRF to pancreatic surgery at the Surgical department of the University Hospital Brno and achieve a decline of postoperative complications. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Petr Morav čík, Jan Hlavsa, Zdeněk Kala, Lumír Kunovský, Vladimír Procházka, Alžběta Kodýtková, Martin Potrusil Tags: 8. Pancreatic Cancer I Source Type: research
Efficacy and safety comparison of nabpaclitaxel plus s-1 and gemcitabine plus s-1 as first-line chemotherapy for metastatic pancreatic cancer
Objectives The retrospective cohort, single-institution analysis was to compare efficacy and safety of nabpaclitaxel plus S-1 (AS) with gemcitabine plus S-1 (GS) as first-line treatment for metastatic pancreatic cancer (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Wenhui Lou, Yuhong Zhou, Xi Guo, Yaolin Xu Tags: 8. Pancreatic Cancer I Source Type: research
Plasma suPAR may distinguish pancreatic cancer from a benign pancreatic disease
Objectives SuPAR (soluble urokinase plasminogen activator receptor) is a marker associated with systemic inflammation and certain malignant diseases. Previously we have shown that it is possible to predict the severity of acute alcohol-induced pancretitis (AAP) (Nikkola et al. Pancreas 2017) and long-term survival after recovery from first AAP (Aronen et al. 2018, submitted) using P-suPAR levels. Urinary suPAR/creatinine ratio is elevated both in chronic pancreatitis (CP), and in pancreatic cancer (PC) (Sorio et al. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Anu Aronen, Janne Aittoniemi, Reetta Huttunen, Anssi Nikkola, Irina Rinta-Kiikka, Jussi Nikkola, Olli Limnell, Isto Nordback, Juhani Sand, Johanna Laukkarinen Tags: 8. Pancreatic Cancer I Source Type: research
Impact of intraoperative microbiological smear analysis of bacterial bile and pancreatic juice colonization on postoperative outcome in patients undergoing pancreaticoduodenectomy for periampullary malignancy
Objectives Patients with underlying periampullary malignancy are at high risk for obstructive jaundice and thus bacterial colonization of bile and pancreatic juice. Studies investigating the impact of bacterial colonization in patients undergoing pancreaticoduodenectomy remain scarce. The aim is to analyze the microbiological results of intraoperative bile and pancreatic juice smear analysis in patients undergoing pancreaticoduodenectomy for periampullary malignancy regarding clinical relevance and correlation to postoperative outcome. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Khalid Alqasim, Fritz Klein, Thomas Malinka, Johann Pratschke, Marcus Bahra Tags: 8. Pancreatic Cancer I Source Type: research
PrEoperAtive biliaRy (PEAR) drainage in malignant biliary obstruction – An observational cohort study to establish a novel score system to evaluate the necessity of biliary decompression prior to operation - Study proposal
Objectives Malignant biliary obstruction is first and the most common symptom in patients with periampullary cancer or cancer of the pancreatic head. For patients with a resectable tumor that have no radiologic evidence of metastasis, surgical resection is the only option for cure. We still do not know which pathophysiologic change or changes in what degree play the main role of the increasement of morbidity and mortality of surgical intervention. (Source: Pancreatology)
Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Tam ás Marjai, Ákos Szücs, Péter Hegyi, Hungarian Pancreatic Study Group Tags: 8. Pancreatic Cancer I Source Type: research
